Clinical Trials
10 trialsNCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT04021082 2023-02-21
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Alexion Pharmaceuticals, Inc.
Phase 2/3 Withdrawn
NCT05239910 2022-10-17
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
Rhizen Pharmaceuticals SA
Phase 2 Withdrawn
NCT03553914 2020-10-19
PLM60 for Peripheral T Cell Lymphoma (PTCL)
Conjupro Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT03355768 2018-12-19
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Columbia University
Phase 3 Withdrawn
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01652014 2016-07-14
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT01769911 2015-05-07
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase NA Withdrawn
NCT01355783 2013-11-18
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
Eisai Inc.
Phase 3 Withdrawn